Drugs / VBR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04820686 | May 2021 → Mar 2023 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04820686 ↗ |
| Action | Inhibit | “VBR is an HBV core protein inhibitor.” NCT04820686 ↗ |
| Route | Oral | “VBR 300 mg tablets orally once daily (QD)” NCT04820686 ↗ |